Potretzke Theodora A, Harvey Jamison A, Gunderson Tina M, Jensen Nicole M, Schmit Grant D, McBane Robert D, Kurup A Nicholas, Wennberg Paul W, Atwell Thomas D
Department of Radiology, Mayo Clinic, 200 First Ave SW, Rochester, MN 55905.
Mayo Clinic School of Medicine, Rochester, MN.
AJR Am J Roentgenol. 2019 Jul;213(1):211-215. doi: 10.2214/AJR.18.20366. Epub 2019 Apr 17.
The purpose of this study is to report the frequency of major bleeding after percutaneous image-guided core biopsy and its association with aspirin usage and duration of prebiopsy aspirin abstinence. A retrospective review of percutaneous image-guided core biopsies performed at our institution between September 1, 2005, and September 1, 2016, was performed ( = 30,966). Patients were excluded if aspirin usage data were missing ( = 633). Bleeding complications were defined using the Common Terminology Criteria for Adverse Events and were considered significant if they were grade 3 or higher. Multivariate models were adjusted for age, sex, platelet count, international normalized ratio, and biopsy target. Three categorizations of aspirin use were examined: any use within 10 days before biopsy, duration of abstinence (> 10 days or no aspirin, 8-10 days, 4-7 days, and 0-3 days before biopsy), and use on the day of biopsy. Associations with bleeding complications were modeled using logistic regression models. A < 0.05 was considered significant. The study included 30,333 biopsies in 21,938 subjects (57% male; median age, 60 years; interquartile range, 49-70 years). Of the biopsies, 7921 (26.1%) were performed in patients who received aspirin within 10 days of biopsy, and 3761 (47.5%) of those biopsies were performed in patients who took aspirin within 3 days. Ninety-eight (0.32%) significant bleeding complications occurred overall, including 34 (0.43%) in patients who used aspirin within 10 days before biopsy (odds ratio, 1.5; 95% CI, 0.96-2.3; = 0.08). Duration of abstinence was associated with a significantly increased bleeding risk only between 0-3 days versus more than 10 days or no aspirin (odds ratio, 2.1; 95% CI, 1.3-3.6; = 0.004). Aspirin use on the day of biopsy showed the greatest increase in risk (1.9%; odds ratio, 6.6; 95% CI, 3.8-11.5; < 0.001). Significant bleeding complications after biopsy remain rare even among patients with recent aspirin usage, although shorter duration of prebiopsy abstinence increases bleeding risk, most significantly if aspirin is taken the day of biopsy.
本研究的目的是报告经皮影像引导下的穿刺活检后严重出血的发生率及其与阿司匹林使用情况和活检前停用阿司匹林时间的关系。对2005年9月1日至2016年9月1日在本机构进行的经皮影像引导下的穿刺活检进行回顾性研究(n = 30,966)。如果阿司匹林使用数据缺失,则将患者排除(n = 633)。使用不良事件通用术语标准定义出血并发症,如果为3级或更高等级,则认为具有临床意义。多变量模型根据年龄、性别、血小板计数、国际标准化比值和活检靶点进行校正。研究了阿司匹林使用的三种分类:活检前10天内的任何使用情况、停用时间(活检前>10天或未使用阿司匹林、8 - 10天、4 - 7天和0 - 3天)以及活检当天的使用情况。使用逻辑回归模型对与出血并发症的相关性进行建模。P < 0.05被认为具有统计学意义。该研究纳入了21,938名受试者的30,333次活检(男性占57%;中位年龄60岁;四分位间距49 - 70岁)。在这些活检中,7921例(26.1%)是在活检前10天内服用阿司匹林的患者中进行的,其中3761例(47.5%)是在活检前3天内服用阿司匹林的患者中进行的。总体发生了98例(0.32%)严重出血并发症,其中活检前10天内使用阿司匹林的患者中有34例(0.43%)(比值比,1.5;95%置信区间,0.96 - 2.3;P = 0.08)。仅在活检前0 - 3天与超过10天或未使用阿司匹林相比,停用时间与出血风险显著增加相关(比值比,2.1;95%置信区间,1.3 - 3.6;P = 0.004)。活检当天使用阿司匹林显示风险增加最大(1.9%;比值比,6.6;95%置信区间,3.8 - 11.5;P < 0.001)。即使在近期使用阿司匹林的患者中,活检后严重出血并发症仍然很少见,尽管活检前停用时间较短会增加出血风险,在活检当天服用阿司匹林时出血风险增加最为显著。